Addex Therapeutics Ltd. — All Filings
252 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
20-F
3
424B3
424B4
424B5
6-K
6-K/A
8-A12B
CERT
CORRESP
D
DEL AM
DRS
DRS/A
DRSLTR
EFFECT
F-1
F-1/A
F-3
NT 20-F
POS AM
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SCHEDULE 13D/A
SEC STAFF LETTER
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 3 | OWNERSHIP DOCUMENT | 0001104659-26-034503 | Mar 25, 2026 | Mar 18, 2026 |
| 3 | OWNERSHIP DOCUMENT | 0001104659-26-034501 | Mar 25, 2026 | Mar 18, 2026 |
| 3 | OWNERSHIP DOCUMENT | 0001104659-26-034498 | Mar 25, 2026 | Mar 18, 2026 |
| 3 | OWNERSHIP DOCUMENT | 0001104659-26-034495 | Mar 25, 2026 | Mar 18, 2026 |
| 3 | OWNERSHIP DOCUMENT | 0001104659-26-034491 | Mar 25, 2026 | Mar 18, 2026 |
| 3 | OWNERSHIP DOCUMENT | 0001104659-26-030243 | Mar 18, 2026 | — |
| 3 | OWNERSHIP DOCUMENT | 0001104659-26-030242 | Mar 18, 2026 | — |
| 3 | OWNERSHIP DOCUMENT | 0001104659-26-030240 | Mar 18, 2026 | — |
| 6-K | FORM 6-K | 0001171843-26-000580 | Feb 3, 2026 | — |
| 6-K | FORM 6-K | 0001171843-26-000110 | Jan 7, 2026 | — |
| 6-K | FORM 6-K | 0001104659-25-119971 | Dec 10, 2025 | — |
| 424B5 | 424B5 | 0001104659-25-119967 | Dec 10, 2025 | — |
| EFFECT | — | 9999999995-25-003556 | Dec 5, 2025 | — |
| 6-K | FORM 6-K | 0001104659-25-118226 | Dec 4, 2025 | — |
| F-3 | F-3 | 0001104659-25-114077 | Nov 19, 2025 | — |
| 6-K | FORM 6-K | 0001171843-25-006744 | Oct 29, 2025 | — |
| 6-K | FORM 6-K | 0001104659-25-094663 | Sep 30, 2025 | Jun 30, 2025 |
| 6-K | FORM 6-K | 0001171843-25-006022 | Sep 23, 2025 | — |
| 6-K | FORM 6-K | 0001171843-25-004208 | Jun 30, 2025 | — |
| 6-K | FORM 6-K | 0001171843-25-004087 | Jun 25, 2025 | — |
| SCHEDULE 13D/A | — | 0001104659-25-061660 | Jun 23, 2025 | — |
| 6-K | FORM 6-K | 0001104659-25-060772 | Jun 20, 2025 | — |
| 6-K | FORM 6-K | 0001171843-25-003746 | Jun 6, 2025 | — |
| 20-F | FORM 20-F | 0001104659-25-049380 | May 15, 2025 | Dec 31, 2024 |
| 6-K | FORM 6-K | 0001171843-25-003038 | May 12, 2025 | — |
| NT 20-F | NT 20-F | 0001104659-25-042472 | Apr 30, 2025 | Dec 31, 2024 |
| 6-K | FORM 6-K | 0001171843-25-002621 | Apr 30, 2025 | — |
| 6-K | FORM 6-K | 0001171843-25-002501 | Apr 25, 2025 | — |
| 6-K | FORM 6-K | 0001171843-25-002264 | Apr 17, 2025 | — |
| 6-K | FORM 6-K | 0001104659-24-121730 | Nov 22, 2024 | — |
| 6-K | FORM 6-K | 0001171843-24-006203 | Nov 12, 2024 | Nov 11, 2024 |
| 6-K | FORM 6-K | 0001104659-24-103840 | Sep 30, 2024 | — |
| 6-K | FORM 6-K | 0001171843-24-005259 | Sep 19, 2024 | — |
| 6-K | FORM 6-K | 0001171843-24-004935 | Aug 27, 2024 | — |
| SC 13D/A | GROWTH EQUITY OPPORTUNITIES FUND IV (ADDEX THERAPEUTICS) - SCHEDULE 13D/A(#7E) | 0001072613-24-000634 | Aug 14, 2024 | — |
| SC 13D/A | GROWTH EQUITY OPPORTUNITIES FUND IV (ADDEX THERAPEUTICS) - SCHEDULE 13D/A(#6) | 0001072613-24-000602 | Aug 5, 2024 | — |
| 6-K | FORM 6-K | 0001171843-24-004045 | Jul 22, 2024 | — |
| 6-K | FORM 6-K | 0001171843-24-003933 | Jul 15, 2024 | — |
| 6-K | FORM 6-K | 0001171843-24-003723 | Jul 1, 2024 | — |
| 6-K | FORM 6-K | 0001104659-24-068801 | Jun 6, 2024 | — |
| 6-K | FORM 6-K | 0001171843-24-003305 | Jun 5, 2024 | — |
| 6-K | FORM 6-K | 0001171843-24-002302 | Apr 29, 2024 | — |
| 424B3 | 424B3 | 0001104659-24-051210 | Apr 24, 2024 | — |
| EFFECT | — | 9999999995-24-001061 | Apr 22, 2024 | — |
| POS AM | POS AM | 0001104659-24-048823 | Apr 18, 2024 | — |
| 20-F | FORM 20-F | 0001104659-24-048532 | Apr 18, 2024 | Dec 31, 2023 |
| 6-K | FORM 6-K | 0001171843-24-002070 | Apr 18, 2024 | — |
| 6-K | FORM 6-K | 0001171843-24-001785 | Apr 3, 2024 | — |
| 424B5 | 424B5 | 0001104659-24-008319 | Jan 30, 2024 | — |
| 6-K | FORM 6-K | 0001104659-24-008318 | Jan 30, 2024 | — |